Skip to main content

Table 4 Association between CPA4 variants and advanced prostate cancer

From: Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer

SNP Genotype Cases, n (%) Controls, n (%) Odds Ratio
(95% CI)*
p-value
rs901799 CC 363 (71.7) 372 (73.5) 1  
  CA 131 (2.6) 121(23.9) 1.11 (0.83 – 1.48) 0.46
  AA 12 (2.4) 13 (2.6) 0.95 (0.43 – 2.1) 0.90
rs3807344 AA 213 (42.1) 201 (39.7) 1  
  AG 221 (43.7) 244 (48.2) 0.85 (0.66 – 1.11) 0.25
  GG 72 (14.2) 61 (12.1) 1.11 (0.75 – 1.65) 0.59
rs1569132 AA 172 (34.0) 165 (32.6) 1  
  AG 234 (46.2) 252 (49.8) 0.89 (0.67 – 1.18) 0.41
  GG 100 (19.8) 89 (17.6) 1.08 (0.75 – 1.54) 0.68
rs1038628 GG 209 (41.3) 212 (41.9) 1  
  GT 220 (43.5) 221 (43.7) 1.01 (0.77 – 1.33) 0.94
  TT 77 (15.2) 73 (14.4) 1.07 (0.73 – 1.57) 0.78
rs2171492 GG 216 (42.7) 212 (41.9) 1  
  GT 216 (42.7) 233 (46.0) 0.91 (0.7 – 1.19) 0.49
  TT 74 (14.6) 61 (12.1) 1.19 (0.8 – 1.77) 0.38
rs1488009 AA 402 (79.4) 387(76.5) 1  
  AG 93 (18.4) 114 (22.5) 0.78 (0.57 – 1.07) 0.12
  GG 11 (2.2) 5 (0.01) 2.12 (0.73 – 6.16) 0.17
  1. * From unconditional logistic regression model, adjusted for age, ethnicity, and medical institution.